These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 21189380)

  • 21. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. One-day DCF regimen in patients with metastatic gastric cancer.
    Dirican A; Kucukzeybek Y; Tarhan MO; Somali I; Erten C; Demir L; Can A; Bayoglu IV; Akyol M; Ekinci N; Medeni M; Koyuncu B; Alacacioglu A
    Tumori; 2013; 99(2):145-8. PubMed ID: 23748805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study.
    Deleporte A; Van den Eynde M; Forget F; Holbrechts S; Delaunoit T; Houbiers G; Kalantari HR; Laurent S; Vanderstraeten E; De Man M; Vergauwe P; Clausse M; Van Der Auwera J; D'Hondt L; Pierre P; Ghillemijn B; Covas A; Paesmans M; Ameye L; Awada A; Sclafani F; Hendlisz A
    Cancer Med; 2021 Jul; 10(13):4366-4374. PubMed ID: 34057299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.
    Mondaca S; Margolis M; Sanchez-Vega F; Jonsson P; Riches JC; Ku GY; Hechtman JF; Tuvy Y; Berger MF; Shah MA; Kelsen DP; Ilson DH; Yu K; Goldberg Z; Epstein AS; Desai A; Chung V; Chou JF; Capanu M; Solit DB; Schultz N; Janjigian YY
    Gastric Cancer; 2019 Mar; 22(2):355-362. PubMed ID: 30088161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.
    El-Rayes BF; Zalupski M; Bekai-Saab T; Heilbrun LK; Hammad N; Patel B; Urba S; Shields AF; Vaishampayan U; Dawson S; Almhanna K; Smith D; Philip PA
    Ann Oncol; 2010 Oct; 21(10):1999-2004. PubMed ID: 20332133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
    Xu J; Bai Y; Xu N; Li E; Wang B; Wang J; Li X; Wang X; Yuan X
    Clin Cancer Res; 2020 Sep; 26(17):4542-4550. PubMed ID: 32561664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).
    Shen L; Li J; Xu J; Pan H; Dai G; Qin S; Wang L; Wang J; Yang Z; Shu Y; Xu R; Chen L; Liu Y; Yu S; Bu L; Piao Y
    Gastric Cancer; 2015 Jan; 18(1):168-76. PubMed ID: 24557418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.
    Sun W; Powell M; O'Dwyer PJ; Catalano P; Ansari RH; Benson AB
    J Clin Oncol; 2010 Jun; 28(18):2947-51. PubMed ID: 20458043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
    Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
    Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
    Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
    Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable locally advanced esophageal and esophagogastric junctional adenocarcinoma.
    Hirose T; Yamamoto S; Honma Y; Yokoyama K; Hirano H; Okita N; Shoji H; Iwasa S; Takashima A; Ishiyama K; Oguma J; Daiko H; Maeda S; Kato K
    Esophagus; 2024 Jul; 21(3):328-335. PubMed ID: 38467986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen.
    Tomasello G; Chiesa MD; Buti S; Brighenti M; Negri F; Rovere RK; Martinotti M; Buononato M; Brunelli A; Lazzarelli S; Donati G; Passalacqua R
    Tumori; 2010; 96(1):48-53. PubMed ID: 20437857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.
    Uronis HE; Bendell JC; Altomare I; Blobe GC; Hsu SD; Morse MA; Pang H; Zafar SY; Conkling P; Favaro J; Arrowood CC; Cushman SM; Meadows KL; Brady JC; Nixon AB; Hurwitz HI
    Oncologist; 2013; 18(3):271-2. PubMed ID: 23485624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction.
    Blum Murphy MA; Qiao W; Mewada N; Wadhwa R; Elimova E; Takashi T; Ho L; Phan A; Baker J; Ajani J
    Am J Clin Oncol; 2018 Apr; 41(4):321-325. PubMed ID: 26908161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
    Evans TR; Pentheroudakis G; Paul J; McInnes A; Blackie R; Raby N; Morrison R; Fullarton GM; Soukop M; McDonald AC
    Ann Oncol; 2002 Sep; 13(9):1469-78. PubMed ID: 12196374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
    Loupakis F; Masi G; Fornaro L; Vasile E; Allegrini G; Fontana E; Granetto C; Salvatore L; Mentuccia L; Andreuccetti M; Cortesi E; Merlano M; Cascinu S; Falcone A
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):559-66. PubMed ID: 20237927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.
    Yoon HH; Bendell JC; Braiteh FS; Firdaus I; Philip PA; Cohn AL; Lewis N; Anderson DM; Arrowsmith E; Schwartz JD; Gao L; Hsu Y; Xu Y; Ferry D; Alberts SR; Wainberg ZA
    Ann Oncol; 2016 Dec; 27(12):2196-2203. PubMed ID: 27765757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial.
    Lorenzen S; Hentrich M; Haberl C; Heinemann V; Schuster T; Seroneit T; Roethling N; Peschel C; Lordick F
    Ann Oncol; 2007 Oct; 18(10):1673-9. PubMed ID: 17660494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
    Ajani JA; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Awad L; Van Cutsem E;
    J Clin Oncol; 2007 Aug; 25(22):3210-6. PubMed ID: 17664468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.